Clal Biotechnology | CBI - Net Income


Clal Biotechnology reported ILS-6.17M in Net Income for its fiscal quarter ending in December of 2022.





Net Income Change Date
Arca Biopharma USD -21M 4.78M Mar/2025
aTyr Pharma USD -25.74M 6.21M Sep/2025
Bio Path USD -2.85M 99K Mar/2025
Brainstorm Cell Therapeutics USD -2.86M 109K Mar/2025
Cara Therapeutics USD -4.91M 2.77M Mar/2025
Clal Biotechnology ILS -6.17M 15.56M Dec/2022
Compugen USD -6.98M 360K Sep/2025
Immunic USD -24.37M 2.99M Sep/2024
Infinity Pharmaceuticals USD -9.96M 1.09M Jun/2023
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
RedHill Biopharma USD -1.54M 0 Jun/2024
TherapeuticsMD USD -1.09M 356K Jun/2024